Literature DB >> 20542893

Assessment of disease activity and progression in Takayasu's arteritis with Disease Extent Index-Takayasu.

Sibel Z Aydin1, Neslihan Yilmaz, Servet Akar, Kenan Aksu, Sevil Kamali, Eftal Yucel, Omer Karadag, Muge Bicakcigil, Huseyin Ozer, Sedat Kiraz, Fatos Onen, Murat Inanc, Gokhan Keser, Nurullah Akkoc, Haner Direskeneli.   

Abstract

OBJECTIVE: Disease Extent Index-Takayasu (DEI.Tak) is a new index developed for the follow-up of Takayasu's arteritis (TA), assessing only clinical findings without the requirement of imaging. We investigated the effectiveness of DEI.Tak in assessing disease activity and progression by comparing with physician's global assessment (PGA) and active disease criteria defined by Kerr et al.
METHODS: The initial DEI.Tak forms were filled in for 145 TA patients cross-sectionally to detect the baseline damage and after 29.8 (31) months (n = 105, 144 visits) only by including the new/worsening symptoms within the past 6 months.
RESULTS: At baseline, all patients had a DEI.Tak >0 [mean (s.d.): 7.6 (4.2)]. At this evaluation, 62% of the patients had active, 16.2% had persistent and 21.8% had inactive disease according to the PGA. At follow-up, in 69% of the patients the DEI.Tak score was 0. However, 14% of them were accepted as having active and 17% persistent disease according to PGA. In contrast, 18% with a DEI.Tak  ≥  1 were inactive according to PGA. Patients with active or persistent disease with PGA had higher DEI.Tak compared with inactives [1.3 (1.9), 1 (1.3) vs 0.2 (0.6), respectively; P < 0.001]. According to Kerr's criteria 27% were active. The total agreement between DEI.Tak and Kerr's criteria was 94% (κ = 0.85). Compared with PGA, Kerr's criteria had a total agreement of 74% and DEI.Tak 68%.
CONCLUSION: During follow-up, most TA patients showed no clinical activity with DEI-Tak. Although the agreement between Kerr's criteria and DEI.Tak seemed very good, using Kerr's criteria instead of DEI.Tak increased the consistency with PGA, which could be explained by the influence of imaging data and acute-phase reactant levels on the physician's decisions.

Entities:  

Mesh:

Year:  2010        PMID: 20542893     DOI: 10.1093/rheumatology/keq171

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  33 in total

1.  Pediatric-onset Takayasu's arteritis: clinical features and short-term outcome.

Authors:  Durga Prasanna Misra; Amita Aggarwal; Able Lawrence; Vikas Agarwal; Ramnath Misra
Journal:  Rheumatol Int       Date:  2015-04-24       Impact factor: 2.631

2.  F-18 FDG PET for assessment of disease activity of large vessel vasculitis: A systematic review and meta-analysis.

Authors:  Sang-Woo Lee; Seong-Jang Kim; Youngduk Seo; Shin Young Jeong; Byeong-Cheol Ahn; Jaetae Lee
Journal:  J Nucl Cardiol       Date:  2018-08-17       Impact factor: 5.952

3.  Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.

Authors:  Haner Direskeneli; Sibel Z Aydin; Tanaz A Kermani; Eric L Matteson; Maarten Boers; Karen Herlyn; Raashid A Luqmani; Tuhina Neogi; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Peter A Merkel
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

Review 4.  Advances in the diagnosis, assessment and outcome of Takayasu's arteritis.

Authors:  Fatma Alibaz-Oner; Sibel Zehra Aydin; Haner Direskeneli
Journal:  Clin Rheumatol       Date:  2012-12-28       Impact factor: 2.980

Review 5.  Clinical diagnosis and management of large vessel vasculitis: Takayasu arteritis.

Authors:  Soumya Chatterjee; Scott D Flamm; Carmela D Tan; E Rene Rodriguez
Journal:  Curr Cardiol Rep       Date:  2014-07       Impact factor: 2.931

Review 6.  Recent advances in Takayasu's arteritis.

Authors:  Fatma Alibaz-Öner; Sibel Zehra Aydın; Haner Direskeneli
Journal:  Eur J Rheumatol       Date:  2015-03-01

Review 7.  Takayasu Arteritis: Recent Developments.

Authors:  Maria L F Zaldivar Villon; Jose A Leon de la Rocha; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2019-07-18       Impact factor: 4.592

Review 8.  Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12.

Authors:  Sibel Zehra Aydin; Haner Direskeneli; Antoine Sreih; Fatma Alibaz-Oner; Ahmet Gul; Sevil Kamali; Gulen Hatemi; Tanaz Kermani; Sarah L Mackie; Alfred Mahr; Alexa Meara; Nataliya Milman; Heidi Nugent; Joanna Robson; Gunnar Tomasson; Peter A Merkel
Journal:  J Rheumatol       Date:  2015-06-15       Impact factor: 4.666

9.  Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016.

Authors:  Antoine G Sreih; Fatma Alibaz-Oner; Tanaz A Kermani; Sibel Z Aydin; Peter F Cronholm; Trocon Davis; Ebony Easley; Ahmet Gul; Alfred Mahr; Carol A McAlear; Nataliya Milman; Joanna C Robson; Gunnar Tomasson; Haner Direskeneli; Peter A Merkel
Journal:  J Rheumatol       Date:  2017-09-01       Impact factor: 4.666

10.  Assessment of Disease Activity in Large-vessel Vasculitis: Results of an International Delphi Exercise.

Authors:  Sibel Z Aydin; Haner Direskeneli; Peter A Merkel
Journal:  J Rheumatol       Date:  2017-09-01       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.